Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6445496 | 1.00 | HCAR2 (0.58) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL94677 | 1.00 | HCAR2 (0.58) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL361271 | 0.85 | HCAR2 (0.59) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL1888855 | 0.85 | HCAR2 (0.59) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL28399684 | 0.85 | HCAR2 (0.52) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL31058784 | 0.82 | HCAR2 (0.46) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL30965305 | 0.82 | HCAR2 (0.46) | HCAR2MAPTNPSR1CA12CA1 | |
| Diethyl Maleate SCHEMBL43033 | 0.82 | HCAR2 (0.80) | HCAR2MAPTNPSR1CA12CA1 | |
| Diethyl Maleate SCHEMBL42602 | 0.82 | HCAR2 (0.80) | HCAR2MAPTNPSR1CA12CA1 | |
| Diethyl Maleate SCHEMBL60423 | 0.82 | HCAR2 (0.80) | HCAR2MAPTNPSR1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 565 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | claimed |
| CN-119371609-A | Curing composition, preparation method and application thereof | 天合光能股份有限公司 | 2025-01-28 | — | — | CN | claimed |
| CN-114015299-A | Preparation and application of composite nano antibacterial and antiviral coating | 宿迁空天新材料有限公司 | 2022-02-08 | — | — | CN | claimed |
| CN-109438237-B | Preparation method of 3-ethoxy ethyl acrylate | 浙江华方药业股份有限公司 | 2021-05-28 | — | — | CN | claimed |
| CN-110003214-A | Substituted pyrazolo [1,5-a] pyrimidine compound as TRK kinase inhibitor | 阵列生物制药公司 | 2019-07-12 | — | — | CN | claimed |
| US-7285686-B2 | Process for the preparation of 1,3-substituted indenes | PFIZER INC (US) | 2007-10-23 | — | — | US | claimed |
| EP-1567483-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES | Pfizer Products Inc. (US) | 2005-08-31 | — | — | EP | claimed |
| US-20050004379-A1 | Process for the preparation of 1,3-substituted indenes | PFIZER INC | 2005-01-06 | — | — | US | claimed |
| WO-2004048318-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 1,3-SUBSTITUTED INDENES | PFIZER PRODUCTS INC. (US) | 2004-06-10 | — | — | WO | claimed |
| US-20030073834-A1 | Purine compounds having PDE IV inhibitory activity and methods of synthesis | CAVALLA DAVID J (GB) | 2003-04-17 | — | — | US | claimed |
| EP-1045850-A4 | PURINE COMPOUNDS HAVING PDE IV INHIBITORY ACTIVITY AND METHODS OF SYNTHESIS | EURO CELTIQUE SA (LU) | 2001-10-31 | — | — | EP | claimed |
| EP-1045850-A1 | PURINE COMPOUNDS HAVING PDE IV INHIBITORY ACTIVITY AND METHODS OF SYNTHESIS | Euro-Celtique S.A. (LU) | 2000-10-25 | — | — | EP | claimed |
| WO-1999029694-A1 | PURINE COMPOUNDS HAVING PDE IV INHIBITORY ACTIVITY AND METHODS OF SYNTHESIS | EURO-CELTIQUE, S.A. (LU) | 1999-06-17 | — | — | WO | claimed |
| EP-0132851-B1 | 5-SUBSTITUTED(1,2,4)TRIAZOLO(1,5-C)PYRIMIDIN-2-AMINES | AMERICAN CYANAMID COMPANY (US) | 1989-10-04 | — | — | EP | claimed |
| EP-0132851-A1 | 5-Substituted(1,2,4)triazolo(1,5-c)pyrimidin-2-amines | AMERICAN CYANAMID COMPANY (US) | 1985-02-13 | — | — | EP | claimed |
| JP-62089642-A | — | — | None | — | — | JP | disclosed |
| US-20260027217-A1 | DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-4579848-A | ANTIASTHMA AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-04-01 | — | — | US | disclosed |
| EP-0132851-A1 | 5-Substituted(1,2,4)triazolo(1,5-c)pyrimidin-2-amines | AMERICAN CYANAMID COMPANY (US) | 1985-02-13 | — | — | EP | disclosed |
| US-4405622-A | [1-(1,4-Benzodioxan-2-yl)-4-(4-aminopyrimidin-2-yl]piperazines useful as anti-depressants | SYNTEX (U.S.A.) INC. (US) | 1983-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027217-A1 | DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF | ALK, IGF1R, PDGFRB | HCAR2 2984/4885MAPT 1393/4885NPSR1 812/4885 |
| US-20050004379-A1 | Process for the preparation of 1,3-substituted indenes | NISCH, DHPS, INA | HCAR2 3945/4885MAPT 430/4885NPSR1 905/4885 |
| US-20030073834-A1 | Purine compounds having PDE IV inhibitory activity and methods of synthesis | PDE3B, PDE3A, PDE4A | HCAR2 1336/4885MAPT 4851/4885NPSR1 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.